Cargando…
MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas
SIMPLE SUMMARY: Renal cell carcinoma (RCC) is the seventh most common cancer type and accounts for more than 80% of all renal tumors. Nevertheless, prognostic biomarkers for RCC are still missing. Therefore, we analyzed a large, multicenter cohort including the three most common RCC subtypes (clear...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996951/ https://www.ncbi.nlm.nih.gov/pubmed/35406537 http://dx.doi.org/10.3390/cancers14071763 |
_version_ | 1784684592623517696 |
---|---|
author | Erlmeier, Franziska Sun, Na Shen, Jian Feuchtinger, Annette Buck, Achim Prade, Verena M. Kunzke, Thomas Schraml, Peter Moch, Holger Autenrieth, Michael Weichert, Wilko Hartmann, Arndt Walch, Axel |
author_facet | Erlmeier, Franziska Sun, Na Shen, Jian Feuchtinger, Annette Buck, Achim Prade, Verena M. Kunzke, Thomas Schraml, Peter Moch, Holger Autenrieth, Michael Weichert, Wilko Hartmann, Arndt Walch, Axel |
author_sort | Erlmeier, Franziska |
collection | PubMed |
description | SIMPLE SUMMARY: Renal cell carcinoma (RCC) is the seventh most common cancer type and accounts for more than 80% of all renal tumors. Nevertheless, prognostic biomarkers for RCC are still missing. Therefore, we analyzed a large, multicenter cohort including the three most common RCC subtypes (clear cell RCC (ccRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC)) by high mass resolution matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) for prognostic biomarker detection. This is a suitable method for biomarker detection for several tumor entities. We detected several pathways and metabolites with prognostic power for RCC in general and also for different RCC subtypes. ABSTRACT: High mass resolution matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) is a suitable method for biomarker detection for several tumor entities. Renal cell carcinoma (RCC) is the seventh most common cancer type and accounts for more than 80% of all renal tumors. Prognostic biomarkers for RCC are still missing. Therefore, we analyzed a large, multicenter cohort including the three most common RCC subtypes (clear cell RCC (ccRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC)) by MALDI for prognostic biomarker detection. MALDI-Fourier-transform ion cyclotron resonance (FT-ICR)-MSI analysis was performed for renal carcinoma tissue sections from 782 patients. SPACiAL pipeline was integrated for automated co-registration of histological and molecular features. Kaplan–Meier analyses with overall survival as endpoint were executed to determine the metabolic features associated with clinical outcome. We detected several pathways and metabolites with prognostic power for RCC in general and also for different RCC subtypes. |
format | Online Article Text |
id | pubmed-8996951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89969512022-04-12 MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas Erlmeier, Franziska Sun, Na Shen, Jian Feuchtinger, Annette Buck, Achim Prade, Verena M. Kunzke, Thomas Schraml, Peter Moch, Holger Autenrieth, Michael Weichert, Wilko Hartmann, Arndt Walch, Axel Cancers (Basel) Article SIMPLE SUMMARY: Renal cell carcinoma (RCC) is the seventh most common cancer type and accounts for more than 80% of all renal tumors. Nevertheless, prognostic biomarkers for RCC are still missing. Therefore, we analyzed a large, multicenter cohort including the three most common RCC subtypes (clear cell RCC (ccRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC)) by high mass resolution matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) for prognostic biomarker detection. This is a suitable method for biomarker detection for several tumor entities. We detected several pathways and metabolites with prognostic power for RCC in general and also for different RCC subtypes. ABSTRACT: High mass resolution matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) is a suitable method for biomarker detection for several tumor entities. Renal cell carcinoma (RCC) is the seventh most common cancer type and accounts for more than 80% of all renal tumors. Prognostic biomarkers for RCC are still missing. Therefore, we analyzed a large, multicenter cohort including the three most common RCC subtypes (clear cell RCC (ccRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC)) by MALDI for prognostic biomarker detection. MALDI-Fourier-transform ion cyclotron resonance (FT-ICR)-MSI analysis was performed for renal carcinoma tissue sections from 782 patients. SPACiAL pipeline was integrated for automated co-registration of histological and molecular features. Kaplan–Meier analyses with overall survival as endpoint were executed to determine the metabolic features associated with clinical outcome. We detected several pathways and metabolites with prognostic power for RCC in general and also for different RCC subtypes. MDPI 2022-03-30 /pmc/articles/PMC8996951/ /pubmed/35406537 http://dx.doi.org/10.3390/cancers14071763 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Erlmeier, Franziska Sun, Na Shen, Jian Feuchtinger, Annette Buck, Achim Prade, Verena M. Kunzke, Thomas Schraml, Peter Moch, Holger Autenrieth, Michael Weichert, Wilko Hartmann, Arndt Walch, Axel MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas |
title | MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas |
title_full | MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas |
title_fullStr | MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas |
title_full_unstemmed | MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas |
title_short | MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas |
title_sort | maldi mass spectrometry imaging—prognostic pathways and metabolites for renal cell carcinomas |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996951/ https://www.ncbi.nlm.nih.gov/pubmed/35406537 http://dx.doi.org/10.3390/cancers14071763 |
work_keys_str_mv | AT erlmeierfranziska maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas AT sunna maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas AT shenjian maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas AT feuchtingerannette maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas AT buckachim maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas AT pradeverenam maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas AT kunzkethomas maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas AT schramlpeter maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas AT mochholger maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas AT autenriethmichael maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas AT weichertwilko maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas AT hartmannarndt maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas AT walchaxel maldimassspectrometryimagingprognosticpathwaysandmetabolitesforrenalcellcarcinomas |